Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, addresses ongoing and future innovations in eye lens technology and instruments for cataract surgery.
Innovations in eye lens technology will continue to focus on improving patient’s functioning, with further progress being made in optimizing the cataract surgery process, said Raj Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson (J&J) Vision.
Transcript
Where do you see eye lens technology going in the next 5 to 10 years?
Certainly continuing to develop technology that continues to improve patient's functioning. We are hoping to continue to be able to provide options that patients can then choose, to minimize their need for glasses after cataract surgery.
We are also continuing to develop the instruments and the technology that's used in cataract surgery. We introduced at J&J Vision this year the VERITAS system, which is the phacoemulsification, or ultrasound system, that actually breaks apart the cataract during surgery.
So, as I was mentioning earlier, during cataract surgery, we make this microscopic incision, and then we use this phacoemulsification equipment, such as VERITAS, to break apart the hard lens. Just like in kidney stones, ultrasound is used to break apart the kidney stone. Then after we've removed all of the cataract, that's when we put the lens implant in place.
As I mentioned earlier, we also have developed and are continuing to develop advances in laser technology that also assist in that cataract surgery process in the operating room.
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More